Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with metronomic S-1 as first-line treatment for advanced primary liver cancer
ChiCTR-OIC-17012124Phase 2Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jun 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and tegafur in hepatocellular carcinoma (HCC), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: progression-free survival. Started Jun 2017; status: recruiting.
02
Drugs
Rivoceranibtegafur
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-OIC-17012124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17012124.